Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefapixant PK study in healthy subjects
NCT02229877Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2014
- Primary completion
- May 2015
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of gefapixant in chronic cough, sponsored by Merck & Co. Primary endpoint: Effect of Intragastric pH on gefapixant PK at 12 hours. Started Oct 2014; status: completed.
02
Drugs
gefapixant
03
Conditions
chronic cough
Beyond the preview
Go deeper on NCT02229877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02229877.